# Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

> **NCT05793450** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** IBI362

## Key facts

- **NCT ID:** NCT05793450
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-05
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-11-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05793450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05793450, "Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05793450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*